

Supplementary Table 2. Percentage of patients with Crohn’s disease or ulcerative colitis with prescriptions of biologics or corticosteroids^a (with and without biologics), by US region, history of smoking, and current alcohol user, 2019 IQVIA

| Patient characteristic | Crohn’s disease | | | | | | | Ulcerative colitis | | | | | | |
|---|-----------------|------------------------|---------|---|---------|--|---------|--------------------|------------------------|---------|---|---------|--|---------|
| | % | Biologics ^b | | Corticosteroids ^c with biologics | | Corticosteroids ^c without biologics | | % | Biologics ^b | | Corticosteroids ^c with biologics | | Corticosteroids ^c without biologics | |
| | | (95% CI) | P value | (95% CI) | P value | (95% CI) | P value | | (95% CI) | P value | (95% CI) | P value | (95% CI) | P value |
| US region | | | | | | | | | | | | | | |
| Northeast | 19.5 | 28.7 (27.8–29.6) | <0.001 | 10.4 (9.8–11.0) | 0.007 | 15.5 (14.8–16.2) | <0.001 | 19.3 | 13.9 (13.2–14.6) | 0.62 | 5.9 (5.4– 6.4) | 0.85 | 18.4 (17.6–19.1) | <0.001 |
| Midwest | 20.0 | 30.7 (29.8–31.6) | 0.05 | 11.0 (10.4–11.6) | 0.33 | 17.6 (16.8–18.3) | 0.54 | 19.4 | 13.3 (12.7–14.0) | 0.06 | 5.9 (5.5– 6.4) | 0.74 | 20.8 (20.0–21.6) | 0.19 |
| South (ref) | 47.4 | 31.7 (31.2–32.3) | — | 11.4 (11.0–11.8) | — | 17.3 (16.8–17.8) | — | 45.8 | 14.1 (13.7–14.5) | — | 5.8 (5.5– 6.1) | — | 20.1 (19.6–20.6) | — |
| West | 13.0 | 27.0 (25.9–28.0) | <0.001 | 10.6 (9.8–11.3) | 0.06 | 18.7 (17.8–19.6) | 0.01 | 15.6 | 12.4 (11.7–13.1) | <0.001 | 6.3 (5.7– 6.8) | 0.18 | 22.9 (22.0–23.8) | <0.001 |
| History of smoking^{d,f} | | | | | | | | | | | | | | |
| Yes | 18.4 | 28.0 (26.8–29.2) | <0.001 | 13.2 (12.5–13.8) | <0.001 | 23.0 (22.1–23.8) | <0.001 | 15.4 | 12.8 (11.8–13.8) | 0.09 | 6.8 (6.3– 7.4) | <0.001 | 25.3 (24.4–26.3) | <0.001 |
| No (ref) | 81.6 | 30.6 (30.1–31.0) | — | 10.5 (10.2–10.8) | — | 15.9 (15.5–16.2) | — | 84.6 | 13.7 (13.4–14.0) | — | 5.8 (5.6– 6.0) | — | 19.4 (19.1–19.8) | — |
| Current alcohol user^{e,f} | | | | | | | | | | | | | | |
| Yes | 30.2 | 33.9 (33.1–34.6) | <0.001 | 10.1 (9.7–10.6) | <0.001 | 14.0 (13.5–14.6) | <0.001 | 31.9 | 15.1 (14.5–15.6) | <0.001 | 5.5 (5.2– 5.9) | 0.01 | 17.1 (16.6–17.7) | <0.001 |
| No (ref) | 69.8 | 28.8 (28.3–29.2) | — | 11.4 (11.1–11.7) | — | 18.5 (18.1–18.9) | — | 68.1 | 13.0 (12.6–13.3) | — | 6.1 (5.9– 6.4) | — | 21.9 (21.4–22.3) | — |

Abbreviations: CI, confidence interval; Ref, referent group.

^aWith or without a biologic prescription within the same calendar year. The denominators are all patients with CD or UC.

^bIncluding adalimumab, infliximab, certolizumab, golimumab, vedolizumab, natalizumab, and ustekinumab.

^cIncluding prednisone, prednisolone, methylprednisolone, hydrocortisone, and budesonide.

^dA history of smoking includes current smokers and former smokers who use cigarettes, tobaccos, or e-cigarettes. It is defined as an affirmative response to both criteria of smoking-related SNOMED codes and clauses “tobacco or cigarette smoking” or “ex-smoker or former smoker”.

^eCurrent alcohol users are patients who currently drink alcohol. It is defined when SNOMED codes are any of ‘219006’, ‘228281002’, and ‘7200002’.

^fThe information for a history of smoking status and current alcohol use status were obtained from another IQVIA database OMOP (Observational Medical Outcomes Partnership) with standardized vocabulary through linkage.